

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the prospectus dated May 28, 2026 (the “**Prospectus**”) of LongBio Pharma (Suzhou) Co., Ltd. (天辰生物醫藥(蘇州)股份有限公司) (the “**Company**”) carefully for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Global Offering should be taken solely in reliance on the information in the Prospectus.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, Sinolink Securities (Hong Kong) Company Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, may, to the extent permitted by applicable laws of Hong Kong or elsewhere, over-allocate or effect transactions with a view to stabilizing or maintaining the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager (its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date, and is expected to expire on Thursday, July 2, 2026, the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

Potential investors of the Offer Shares should note that the Sole Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Friday, June 5, 2026).

longbio

天辰生物

LongBio Pharma (Suzhou) Co., Ltd.

天辰生物醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

## GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 14,193,150 H Shares (subject to the Over-allotment Option)  
Number of Hong Kong Offer Shares : 1,419,350 H Shares  
Number of International Offer Shares : 12,773,800 H Shares (subject to the Over-allotment Option)  
Offer Price : HK\$96.06 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%  
Nominal value : RMB1.00 per H Share  
Stock Code : 01779

*Sole Sponsor, Sole Sponsor-Overall Coordinator, Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager*



*Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*



# LongBio Pharma (Suzhou) Co., Ltd.

## 天辰生物醫藥(蘇州)股份有限公司

### ANNOUNCEMENT OF ALLOTMENT RESULTS

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

#### SUMMARY

Company information	
Stock code	01779
Stock short name	LONGBIO-B
Dealings commencement date	June 5, 2026*

\* see note at the end of the announcement

Price Information	
Final Offer Price	HK\$96.06

Offer Shares and Share Capital	
Number of Offer Shares (before exercise of the Over-allotment Option)	14,193,150 H Shares
Number of Offer Shares in Hong Kong Public Offering	1,419,350 H Shares
Number of Offer Shares in International Offering (before exercise of the Over-allotment Option)	12,773,800 H Shares
Number of issued Shares upon Listing (before exercise of the Over-allotment Option)	74,193,150 Shares

Over-allocation	
Number of Offer Shares over-allocated	2,128,950 H Shares

*Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.*

Proceeds	
Gross proceeds (Note)	HK\$1,363.4 million
Less: Estimated listing expenses payable based on Offer Price	HK\$108.5 million
Net proceeds	HK\$1,254.9 million

*Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed "Future Plans and Use of Proceeds" of the Prospectus. The Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus on a pro rata basis.*

## ALLOTMENT RESULTS DETAILS

### HONG KONG PUBLIC OFFERING

No. of valid applications	266,377
No. of successful applications	28,057
Subscription level	4,762.58 times
Reallocation	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	1,419,350 H Shares
No. of Offer Shares reallocated from the International Offering	0
Final no. of Offer Shares under the Hong Kong Public Offering	1,419,350 H Shares
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	10.00%

*Note: For details of the final allocation of Offer Shares to the Hong Kong Public Offering, investors can refer to [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) to perform a search by identification document number or [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) for the full list of allottees.*

### INTERNATIONAL OFFERING

No. of placees	80
Subscription Level	10.94 times
No. of Offer Shares initially available under the International Offering	12,773,800 H Shares
No. of Offer Shares reallocated to the Hong Kong Public Offering	0
Final no. of Offer Shares under the International Offering	12,773,800 H Shares
% of Offer Shares under the International Offering to the Global Offering	90.00%

*The Directors confirm that, to the best of their knowledge, information and belief, save for consents under paragraphs 1C(1) and 1C(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) and under Chapters 2.3 and 4.15 of the Guide for New Listing Applicants (“**Guide**”) granted by the Stock Exchange to permit the Company to, among other things, allocate certain Offer Shares in the International Offering to certain close associates of existing Shareholders and certain connected clients, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.*

The placees in the International Offering include the following:

### Cornerstone Investors

<i>Investor</i> <sup>Note 1</sup>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Existing shareholders or their close associates</i>
OrbiMed Genesis Master Fund, L.P. (“ <b>OrbiMed Genesis</b> ”) <sup>Note 2</sup>	969,900	6.83%	1.31%	No
The Biotech Growth Trust PLC (“ <b>BIOG</b> ”) <sup>Note 2</sup>	497,150	3.50%	0.67%	No
TruMed Health Innovation Fund LP (“ <b>TruMed Innovation Fund</b> ”) <sup>Note 3</sup>	692,650	4.88%	0.93%	Yes
TruMed Healthcare Master Fund (“ <b>TruMed Master Fund</b> ”) <sup>Note 3</sup>	285,200	2.01%	0.38%	Yes
Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥)) (“ <b>Shanghai Gaoyi</b> ”) and Huatai Capital Investment Limited (“ <b>HTCI</b> ”) (in connection with Huatai Back-to-back TRS and the Huatai Client TRS)	978,050	6.89%	1.32%	No
Wisdomshire Asset Management Co., Ltd* (上海睿郡資產管理有限公司) (“ <b>Wisdomshire AM</b> ”) and HTCI (in connection with Huatai Back-to-back TRS and the Huatai Client TRS)	652,000	4.59%	0.88%	No
Foresight Global Superior Choice SPC — Vision Fund 1 SP (“ <b>Vision Fund 1</b> ”) <sup>Note 4</sup>	474,650	3.34%	0.64%	No
Foresight Global Superior Choice SPC — Global Superior Choice Fund 1 SP (“ <b>GSC Fund 1</b> ”) <sup>Note 4</sup>	258,900	1.82%	0.35%	No
Foresight Global Superior Choice SPC — Horizon Fund 1 SP (“ <b>Horizon Fund 1</b> ”) <sup>Note 4</sup>	40,750	0.29%	0.05%	No
Foresight Global Superior Choice SPC — Horizon Next Fund SP (“ <b>Horizon Next Fund</b> ”) <sup>Note 4</sup>	40,750	0.29%	0.05%	No
Fullgoal Fund Management Co., Ltd. (富國基金管理有限公司) (“ <b>Fullgoal Fund</b> ”) <sup>Note 5</sup>	685,450	4.83%	0.92%	No
Fullgoal Asset Management (HK) Limited (富國資產管理(香港)有限公司) (“ <b>Fullgoal HK</b> ”) <sup>Note 5</sup>	129,550	0.91%	0.17%	No
Value Partners Hong Kong Limited (“ <b>VPHKL</b> ”) <sup>Note 6</sup>	570,400	4.02%	0.77%	No
Value Partners Limited (“ <b>VPL</b> ”) <sup>Note 6</sup>	81,500	0.57%	0.11%	No
Greater Bay Area Development Fund Management Limited for and on behalf of the managed account of Mega Prime Development Limited (“ <b>Mega Prime</b> ”) <sup>Note 6</sup>	407,500	2.87%	0.55%	No
FR M CONSULTING CO., LTD (“ <b>FR M</b> ”) <sup>Note 6</sup>	163,000	1.15%	0.22%	No
Yuanfeng Future Growth Private Equity Securities Investment Fund* (源峰遠景成長私募證券投資基金) (“ <b>Yuanfeng Future Growth Fund</b> ”) and China Galaxy International Investment Company Limited (“ <b>CGII</b> ”) (in connection with the Yuanfeng OTC Swaps)	163,000	1.15%	0.22%	No
<b>Total</b>	<b>7,090,400</b>	<b>49.96%</b>	<b>9.56%</b>	

*Notes:*

- (1) *For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.*
- (2) *As disclosed in the Prospectus, OrbiMed Genesis is an exempted limited partnership incorporated in the Cayman Islands. OrbiMed Genesis GP LLC (“**Genesis GP**”) is the general partner of OrbiMed Genesis. OrbiMed Advisors LLC (“**OrbiMed Advisors**”) is the managing member of Genesis GP. BIOG is a publicly listed trust organized under the laws of England. OrbiMed Capital LLC (“**OrbiMed Capital**”) is the portfolio manager of BIOG. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, all of whom are Independent Third Parties. The management committee has sole discretion in exercising such voting and investment power on behalf of OrbiMed Advisors and OrbiMed Capital.*
- (3) *As disclosed in the Prospectus, TruMed Innovation Fund is a limited partnership incorporated in the Cayman Island. Its general partner is TruMed Health Innovation Fund GP Limited, which is wholly owned by Ms. Ting Wang. TruMed Master Fund is a healthcare-focused pooled investment fund managed by TruMed Investment Management Limited as investment manager with discretionary authority. TruMed Investment Management Limited is wholly owned by Ms. Ting Wang. TruMed Innovation Fund and TruMed Master Fund are therefore under the common control of Ms. Ting Wang. Each of TruMed Innovation Fund and TruMed Master Fund is a close associate of Hainan Renze Zhenji Venture Capital Fund Partnership Enterprise (Limited Partnership) (海南仁澤真寄創業投資基金合夥企業(有限合夥)), which holds approximately 0.30% of the total issued Shares immediately prior to the Global Offering. The Stock Exchange has given consent under paragraph 1C(2) of the Placing Guidelines to permit each of TruMed Innovation Fund and TruMed Master Fund to participate in the International Offering as a Cornerstone Investor. Please refer to the section headed “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the Prospectus and “Others/Additional Information” in this announcement for details.*
- (4) *As disclosed in the Prospectus, Vision Fund 1, GSC Fund 1, Horizon Fund 1 and Horizon Next Fund are all sub funds of Foresight Global Superior Choice SPC.*
- (5) *As disclosed in the Prospectus, Fullgoal HK is a wholly owned subsidiary of Fullgoal Fund.*
- (6) *As disclosed in the Prospectus, VPHKL and VPL are wholly-owned subsidiaries of Value Partners Group Limited, a company listed on the Stock Exchange (stock code: 806). Each of VPHKL and VPL is a connected client of GF Securities (Hong Kong) Brokerage Limited. The Stock Exchange has given consent under paragraph 1C(1) of the Placing Guidelines in relation to the allocation of Offer Shares to each of VPHKL and VPL as Cornerstone Investors. Please refer to the section headed “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the Prospectus and “Others/Additional Information” in this announcement for details.*

## Allottees with Waivers/Consents Obtained

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
<i>Allottees with consent under paragraph 1C(2) of the Placing Guidelines under Chapters 2.3 and 4.15 of the Guide in relation to allocation of Offer Shares to close associates of existing Shareholders</i> <sup>Note 1</sup>				
TruMed Innovation Fund	692,650	4.88%	0.93%	A close associate of an existing Shareholder
TruMed Master Fund	285,200	2.01%	0.38%	A close associate of an existing Shareholder
O F CAPITAL TECH LPF (“OFC Tech”)	16,100	0.11%	0.02%	A close associate of an existing Shareholder
Changshu Kunsheng Equity Investment Fund Partnership Enterprise (Limited Partnership) (常熟昆晟股權投資基金合夥企業 (有限合夥)) (“Changshu Kunsheng”) <sup>Note 2</sup>	806,850	5.68%	1.09%	A close associate of an existing Shareholder
Changshu Guofa Venture Capital Co., Ltd. (常熟市國發創業投資有限公司) (“Changshu Guofa”) <sup>Note 2</sup>	403,400	2.84%	0.54%	A close associate of an existing Shareholder
<i>Allottees with consents under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide in relation to allocations to connected clients</i> <sup>Note 3</sup>				
VPHKL	570,400	4.02%	0.77%	A connected client
VPL	81,500	0.57%	0.11%	A connected client
GF International Investment Management Limited (“GF International Investment”) <sup>Note 4</sup>	806,850	5.68%	1.09%	A connected client
E Fund Management Co., Ltd. (“E Fund”) <sup>Note 5</sup>	57,450	0.40%	0.08%	A connected client
E Fund Management (Hong Kong) Co., Ltd. (“E Fund HK”) <sup>Note 5</sup>	7,100	0.05%	0.01%	A connected client
GF Securities Asset Management (Guangdong) Co., Ltd. (“GF Securities AM”) <sup>Note 4</sup>	8,500	0.06%	0.01%	A connected client
Orient Asset Management (Hong Kong) Limited (“Orient AM”)	800	0.01%	0.001%	A connected client

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
-----------------	--------------------------------------	--	---	---------------------

*Notes:*

- (1) *The Stock Exchange has given a consent under paragraph 1C(2) of the Placing Guidelines and Chapters 2.3 and 4.15 of Guide permit Offer Shares be placed the above placees who are close associates of existing Shareholders. Please refer to the section headed “Others/Additional Information” in this announcement.*
- (2) *Changshu Kunsheng is a limited partnership established in the PRC, whose general partner is Changshu Kaisheng Southeast Entrepreneurship Investment Management Co., Ltd. (常熟開晟東南創業投資管理有限公司) (“**Changshu Kaisheng**”) with 1% partnership interest therein. Changshu Guofa is a company established in the PRC with limited liability. Changshu Kaisheng and Changshu Guofa are all indirectly wholly-owned by the Bureau of Finance of Changshu (Changshu Municipal Government State-owned Assets Supervision and Administration Office) (常熟市財政局(常熟市政府國有資產監督管理辦公室)) (“**Changshu SASAO**”). Changshu Kunsheng and Changshu Guofa subscribed for the H Shares through certain Qualified Domestic Institutional Investors.*
- (3) *For details of the consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide in relation to allocations to connected clients, please refer to the section headed “Others/Additional Information” in this announcement.*
- (4) *GF International Investment is an indirect non-wholly owned subsidiary of GF Securities Co., Ltd. (廣發證券股份有限公司) (“**GF Securities**”), a company listed on the Shenzhen Stock Exchange (stock code: 000776.SZ). GF Securities AM is a direct wholly-owned subsidiary of GF Securities. Please refer to the section headed “Others/Additional Information” in this announcement for details.*
- (5) *E Fund HK is a wholly-owned subsidiary of E Fund. Please refer to the section headed “Others/Additional Information” in this announcement for details.*

## LOCK-UP UNDERTAKINGS

### *Cornerstone Investors*

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings <sup>Note 1</sup></i>
OrbiMed Genesis	969,900 H Shares	1.33%	1.31%	December 4, 2026
BIOG	497,150 H Shares	0.68%	0.67%	December 4, 2026
TruMed Innovation Fund	692,650 H Shares	0.95%	0.93%	December 4, 2026
TruMed Master Fund	285,200 H Shares	0.39%	0.38%	December 4, 2026
Shanghai Gaoyi and HTCI (in connection with Huatai Back-to-back TRS and the Huatai Client TRS)	978,050 H Shares	1.34%	1.32%	December 4, 2026
Wisdomshire AM and HTCI (in connection with Huatai Back-to-back TRS and the Huatai Client TRS)	652,000 H Shares	0.89%	0.88%	December 4, 2026
Vision Fund 1	474,650 H Shares	0.65%	0.64%	December 4, 2026
GSC Fund 1	258,900 H Shares	0.35%	0.35%	December 4, 2026
Horizon Fund 1	40,750 H Shares	0.06%	0.05%	December 4, 2026
Horizon Next Fund	40,750 H Shares	0.06%	0.05%	December 4, 2026
Fullgoal Fund	685,450 H Shares	0.94%	0.92%	December 4, 2026
Fullgoal HK	129,550 H Shares	0.18%	0.17%	December 4, 2026
VPHKL	570,400 H Shares	0.78%	0.77%	December 4, 2026
VPL	81,500 H Shares	0.11%	0.11%	December 4, 2026
Mega Prime	407,500 H Shares	0.56%	0.55%	December 4, 2026
FR M	163,000 H Shares	0.22%	0.22%	December 4, 2026
Yuanfeng Future Growth Fund and CGII (in connection with the Yuanfeng OTC Swaps)	163,000 H Shares	0.22%	0.22%	December 4, 2026
<b>Subtotal</b>	<b>7,090,400 H Shares</b>	<b>9.72%</b>	<b>9.56%</b>	

*Note:*

- (1) *In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December 4, 2026, being six months following the Listing Date. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.*

## Controlling Shareholders

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings <sup>Note 1</sup></i>
Liu Heng (劉恒)	8,447,692 H Shares	11.58%	11.39%	June 4, 2027
Sun Bill Nai-chau (孫乃超)	6,668,921 H Shares	9.14%	8.99%	June 4, 2027
Suzhou Taiwu Enterprise Management Partnership (Limited Partnership) (蘇州泰悟企業管理合夥企業(有限合夥))	4,899,364 H Shares	6.72%	6.60%	June 4, 2027
Sun Cecily Rou-yun (周若芸)	3,643,748 H Shares	5.00%	4.91%	June 4, 2027
Shanghai Rising Suns Biomedical Inc. (上海九日生物醫藥有限公司)	2,154,243 H Shares	2.95%	2.90%	June 4, 2027
PharMab, Inc. (旭華(上海)生物研發中心有限公司)	683,191 H Shares	0.94%	0.92%	June 4, 2027
<b>Total</b>	<b>26,497,159 H Shares</b>	<b>36.33%</b>	<b>35.71%</b>	

*Note:*

- (1) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Controlling Shareholders ends on June 4, 2027, being twelve months following the Listing Date. Pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders has undertaken to the Stock Exchange and the Company that, he, she or it shall comply with the applicable lock-up requirements. For further details, please refer to the section headed “Underwriting – Undertakings to the Stock Exchange Pursuant to the Listing Rules – Undertakings by our Controlling Shareholders” in the Prospectus.

***Other Existing Shareholders (including the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)***

<b><i>Name</i></b>	<b><i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i></b>	<b><i>Number of H Shares held in the Company as a % of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i></b>	<b><i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i></b>	<b><i>Last day subject to the lock-up undertakings</i></b> <i>Note 1 and Note 2</i>
Huzhou Youxing Venture Capital Partnership Enterprise (Limited Partnership) (湖州友星創業投資合夥企業(有限合夥)) (“ <b>Huzhou Youxing</b> ”) <i>Note 3</i>	7,021,810 H Shares	9.63%	9.46%	June 4, 2027
Suzhou Youxin Venture Capital Partnership Enterprise (Limited Partnership) (蘇州友信創業投資合夥企業(有限合夥)) (“ <b>Suzhou Youxin</b> ”) <i>Note 3</i>	3,203,667 H Shares	4.39%	4.32%	June 4, 2027
Suzhou Lianrui Venture Capital Partnership Enterprise (Limited Partnership) (蘇州連銳創業投資合夥企業(有限合夥)) (“ <b>Suzhou Lianrui</b> ”) <i>Note 3</i>	1,641,884 H Shares	2.25%	2.21%	June 4, 2027
Huzhou Youcheng Venture Capital Partnership Enterprise (Limited Partnership) (湖州友成創業投資合夥企業(有限合夥)) (“ <b>Huzhou Youcheng</b> ”) <i>Note 3</i>	866,867 H Shares	1.19%	1.17%	June 4, 2027
Fuhai Ancheng Bohui (Bozhou) Healthcare Equity Investment Fund Partnership Enterprise (Limited Partnership) (富海安誠博暉(亳州)醫療股權投資基金合夥企業(有限合夥)) (“ <b>OFC Bohui Fund</b> ”) <i>Note 4</i>	3,077,490 H Shares	4.22%	4.15%	June 4, 2027
China SME Development Fund (Chengdu) Jiaozi Venture Capital Investment Partnership Enterprise (Limited Partnership) (中小企業發展基金(成都)交子創業投資合夥企業(有限合夥)) (“ <b>OFC Jiaozi Fund</b> ”) <i>Note 4</i>	1,171,447 H Shares	1.61%	1.58%	June 4, 2027
Huzhou Yongshi Huijin Venture Capital Partnership Enterprise (Limited Partnership) (湖州永石匯金創業投資合夥企業(有限合夥)) (“ <b>Yongshi Huijin</b> ”) <i>Note 5</i>	1,025,832 (including 512,916 H Shares)	0.70%	1.38%	June 4, 2027

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company as a % of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i> <i>Note 1 and Note 2</i>
Huzhou Yongshi Weizhen Venture Capital Investment Partnership Enterprise (Limited Partnership) (湖州永石唯真創業投資合夥企業(有限合夥)) (“Yongshi Weizhen”) <i>Note 5</i>	1,499,932 (including 749,966 H Shares)	1.03%	2.02%	June 4, 2027
HLC VGC Partners HK II Limited (“HLC”) <i>Note 6</i>	1,290,964 H Shares	1.77%	1.74%	June 4, 2027
Qingdao Hongyi Investment Partnership (Limited Partnership) (青島弘燭投資合夥企業(有限合夥)) (“Qingdao Hongyi”) <i>Note 6</i>	1,099,710 H Shares	1.51%	1.48%	June 4, 2027
QM282 Limited	1,921,283 H Shares	2.63%	2.59%	June 4, 2027
Qingdao CSPC Sangel New Drug Investment Partnership Enterprise (Limited Partnership) (青島石藥仙瞳新藥投資合夥企業(有限合夥))	1,538,745 H Shares	2.11%	2.07%	June 4, 2027
Shanghai Lingang Pioneer Innovation Private Equity Investment Fund Partnership L.P. (上海臨港啟創生科私募投資基金合夥企業(有限合夥))	1,045,922 H Shares	1.43%	1.41%	June 4, 2027
Changshu Southeast Industrial Investment Co., Ltd. (常熟東南產業投資有限公司) (“Southeast Investment”) <i>Note 7</i>	1,025,832 H Shares	1.41%	1.38%	June 4, 2027
Changshu Wuyue Angel Venture Capital Partnership Enterprise (Limited Partnership) (常熟吳越天使創業投資合夥企業(有限合夥)) (“Changshu Wuyue Angel”) <i>Note 7</i>	390,484 H Shares	0.54%	0.53%	June 4, 2027
Shanxi Securities Alternative Investment Ltd (山證創新投資有限公司)	954,287 H Shares	1.31%	1.29%	June 4, 2027
Anhui Anyuan Modern Health Industry Investment Center (Limited Partnership) (安徽安元現代健康產業投資中心(有限合夥))	820,662 H Shares	1.13%	1.11%	June 4, 2027

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company as a % of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i> <i>Note 1 and Note 2</i>
Hangzhou Beicheng Venture Capital Partnership (Limited Partnership Enterprise) (杭州貝橙創業投資合夥企業(有限合夥))	747,085 H Shares	1.02%	1.01%	June 4, 2027
Changshu Sanyi No. 1 Venture Capital Partnership Enterprise (Limited Partnership) (常熟三奕壹號創業投資合夥企業(有限合夥))	727,654 H Shares	1.00%	0.98%	June 4, 2027
Hangzhou Qiming Rongjing Equity Investment Partnership Enterprise (Limited Partnership) (杭州啟明融晶股權投資合夥企業(有限合夥)) (“Qiming Rongjing”) <i>Note 8</i>	384,255 H Shares	0.53%	0.52%	June 4, 2027
Suzhou Qiming Rongqian Equity Investment Partnership (Limited Partnership Enterprise) (蘇州啟明融乾股權投資合夥企業(有限合夥)) (“Qiming Rongqian”) <i>Note 8</i>	256,176 H Shares	0.35%	0.35%	June 4, 2027
Hefei Hongta Industrial Investment Partnership (Limited Partnership) (合肥弘沓產業投資合夥企業(有限合夥))	585,726 H Shares	0.80%	0.79%	June 4, 2027
Shenzhen Sangel Shunchuang Biomedical Angel Investment Partnership Enterprise (Limited Partnership) (深圳仙瞳順創生物醫療天使投資合夥企業(有限合夥))	512,913 H Shares	0.70%	0.69%	June 4, 2027
Shenzhen Xinsheng Huachuang Enterprise Management Partnership (Limited Partnership) (深圳市新生華創企業管理合夥企業(有限合夥))	512,913 H Shares	0.70%	0.69%	June 4, 2027
Hainan Renze Zhenji Venture Capital Fund Partnership Enterprise (Limited Partnership) (海南仁澤真寄創業投資基金合夥企業(有限合夥))	179,301 H Shares	0.25%	0.24%	June 4, 2027
<b>Total</b>	<b>33,502,841 (including 32,239,959 H Shares)</b>	<b>44.21%</b>	<b>45.16%</b>	

*Notes:*

- (1) Under the applicable PRC laws, all existing Shareholders (including Pre-IPO Investors) are subject to a lock-up period of twelve months following the Listing Date.*
- (2) The numbers of Shares held by OFC Bohui Fund, OFC Jiaozi Fund, Southeast Investment, Changshu Wuyue Angel and Hainan Renze in the table above do not take into account the Shares to be subscribed by their respective close associates in the Global Offering. The Company has applied to the Stock Exchange for, and the Stock Exchange has given to the Company, a consent under paragraph 1C(2) of the Placing Guidelines permit the Company to allocate such Offer Shares in the International Offering to their respective close associates. For details, please refer to the sections headed “Allottees with Waivers/Consents Obtained” and “Others/Additional Information” in this announcement.*
- (3) As disclosed in the Prospectus, each of Huzhou Youxing, Suzhou Youxin, Suzhou Lianrui and Huzhou Youcheng is a limited partnership established in the PRC, and the executive partner and fund manager of which is Shanghai Tongrui Investment Management Company Limited.*
- (4) As disclosed in the Prospectus, OFC Bohui Fund and OFC Jiaozi Fund, both of which are limited partnerships established in the PRC, are venture capital investment funds whose investment and asset management affairs are managed and controlled by its respective fund managers, being Oriental Fortune (Wuhu) Equity Investment Fund Management Enterprise (Limited Partnership) (東方富海(蕪湖)股權投資基金管理企業(有限合夥)) (“**OFC Wuhu**”) and Shenzhen Oriental Fortune Venture Capital Investment Management Co., Ltd. (深圳市東方富海創業投資管理有限公司) (“**OFC VC Investment**”). Each of OFC VC Investment and OFC Wuhu is a direct or indirect wholly owned subsidiary of Shenzhen Oriental Fortune Capital Investment Management Co., Ltd. (深圳市東方富海投資管理股份有限公司) (“**Oriental Fortune Capital**”). OFC Wuhu is owned by Oriental Fortune Capital and OFC VC Investment as to 95% and 5%, respectively, and OFC VC Investment is in turn wholly owned by Oriental Fortune Capital.*
- (5) As disclosed in the Prospectus, each of Yongshi Huijin and Yongshi Weizhen is limited partnership established in the PRC, and the executive partner and fund manager of which is Huzhou Yongshi Equity Investment Management Co., Ltd. (湖州永石股權投資管理有限公司).*
- (6) As disclosed in the Prospectus, HLC is a company incorporated in Hong Kong with limited liability, and it is wholly owned by HLC VGC Fund IV L.P.. HLC VGC Fund IV L.P. is an exempted limited partnership established under the laws of the Cayman Islands and is ultimately managed by its general partner HLC VGC GP IV Limited, and in turn ultimately controlled by Mr. WANG Hui (王暉). Qingdao Hongyi is a limited partnership established in the PRC and managed by its executive partner, Shanghai Hehong Jinghui Equity Investment Management Co., Ltd. (上海合弘景暉股權投資管理有限公司) (“**Shanghai Hehong Jinghui**”). Shanghai Hehong Jinghui is also ultimately controlled by Mr. WANG Hui (王暉) and is owned as to 72% by him.*
- (7) As disclosed in the Prospectus, Southeast Investment is a company established in the PRC with limited liability. It is owned by Changshu Southeast Investment Holding Co., Ltd. (常熟市東南投資控股有限公司) as to 99.96%, which is in turn indirectly wholly owned by Changshu SASAO. Changshu Wuyue Angel is a limited partnership established in the PRC. Among the limited partners of Changshu Wuyue Angel, Changshu Investment Holdings Group Co., Ltd. (常熟市投資控股集團有限公司) holds approximately 52.89% of the partnership interests. Changshu Investment Holdings Group Co., Ltd. is wholly owned by Changshu State-owned Capital Investment and Operation Group Co., Ltd. (常熟市國有資本投資運營集團有限公司) which is in turn wholly owned by Changshu SASAO. The executive partner of Changshu Wuyue Angel is Changshu Qixin Venture Capital Partnership (Limited Partnership) (常熟啟新創業投資合夥企業(有限合夥)), which is owned as to 35% by Changshu Guofa as its executive partner and as to 35% by SIP Oriza Seed Fund Management Co., LTD. (蘇州工業園區元禾原點創業投資管理有限公司). Changshu Guofa is indirectly wholly-owned by the Changshu SASAO.*
- (8) As disclosed in the Prospectus, Qiming Rongjing and Qiming Rongqian are limited partnerships established in the PRC, with their general partner being Suzhou Qikun Venture Capital Partnership (Limited Partnership) (蘇州啟坤創業投資合夥企業(有限合夥)).*

## PLACEE CONCENTRATION ANALYSIS

Placees	* Number of H Shares allotted	Allotment as % of International Offering (assuming the Option is exercised and new H Shares are issued)		Allotment as % of total Offer Shares (assuming the Option is exercised and new H Shares are issued)		Number of H Shares held upon Listing	% of total issued share capital upon Listing (assuming the Option is exercised and new H Shares are issued)	
		Over-allotment Option)	Over-allotment Option)	Over-allotment Option)	Over-allotment Option)		Over-allotment Option)	Over-allotment Option)
Top 1	1,467,050	11.5%	9.8%	10.3%	9.0%	1,467,050	2.0%	1.9%
Top 5	5,513,100	43.2%	37.0%	38.8%	33.8%	6,929,416	9.3%	9.1%
Top 10	9,144,850	71.6%	61.4%	64.4%	56.0%	10,561,166	14.2%	13.8%
Top 25	13,735,500	107.5%	92.2%	96.8%	84.2%	15,151,816	20.4%	19.9%

*Note:*

\* Ranking of placees is based on the number of H Shares allotted to the placees.

## H SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders	* Number of H Shares allotted	Allotment as % of International Offering (assuming the Option is exercised and new H Shares are issued)		Allotment as % of total Offer Shares (assuming the Option is exercised and new H Shares are issued)		Number of H Shares held upon Listing	% of total issued share capital upon Listing (assuming the Option is exercised and new H Shares are issued)	
		Over-allotment Option)	Over-allotment Option)	Over-allotment Option)	Over-allotment Option)		Over-allotment Option)	Over-allotment Option)
Top 1	–	0.0%	0.0%	0.0%	0.0%	26,497,159	36.3%	35.3%
Top 5	1,226,350	9.6%	8.2%	8.6%	7.5%	48,513,664	66.5%	64.6%
Top 10	3,671,250	28.7%	24.6%	25.9%	22.5%	55,860,775	76.6%	74.4%
Top 25	9,812,850	76.8%	65.8%	69.1%	60.1%	67,524,142	92.6%	90.0%

*Note:*

\* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

## SHAREHOLDER CONCENTRATION ANALYSIS

	Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued)					% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)		
	* Number of H Shares allotted	exercise of the Over-allotment Option)	exercised and new H Shares are issued)	exercise of the Over-allotment Option)	is exercised and new H Shares are issued)	Number of Shares held upon Listing	exercise of the Over-allotment Option)	exercised and new H Shares are issued)
All Shareholders								
Top 1	–	0.0%	0.0%	0.0%	0.0%	26,497,159	35.7%	34.7%
Top 5	1,226,350	9.6%	8.2%	8.6%	7.5%	48,513,664	65.4%	63.6%
Top 10	3,671,250	28.7%	24.6%	25.9%	22.5%	57,123,657	77.0%	74.8%
Top 25	9,812,850	76.8%	65.8%	69.1%	60.1%	68,787,024	92.7%	90.1%

*Note:*

\* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon Listing.*

## BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

<b>Pool A</b>			
<b>Number of H Shares applied for</b>	<b>Number of valid applications</b>	<b>Basis of allocation/ballot</b>	<b>Approximate percentage allotted of the total number of H Shares applied for</b>
50	51,154	1,024 out of 51,154 applicants to receive 50 H Shares	2.00%
100	27,227	679 out of 27,227 applicants to receive 50 H Shares	1.25%
150	5,797	165 out of 5,797 applicants to receive 50 H Shares	0.95%
200	5,425	169 out of 5,425 applicants to receive 50 H Shares	0.78%
250	4,451	149 out of 4,451 applicants to receive 50 H Shares	0.67%
300	3,614	128 out of 3,614 applicants to receive 50 H Shares	0.59%
350	2,817	105 out of 2,817 applicants to receive 50 H Shares	0.53%
400	2,587	100 out of 2,587 applicants to receive 50 H Shares	0.48%
450	1,718	69 out of 1,718 applicants to receive 50 H Shares	0.45%
500	17,860	741 out of 17,860 applicants to receive 50 H Shares	0.41%
600	2,605	115 out of 2,605 applicants to receive 50 H Shares	0.37%
700	2,131	99 out of 2,131 applicants to receive 50 H Shares	0.33%
800	2,255	109 out of 2,255 applicants to receive 50 H Shares	0.30%
900	2,417	121 out of 2,417 applicants to receive 50 H Shares	0.28%
1,000	12,501	647 out of 12,501 applicants to receive 50 H Shares	0.26%
1,500	5,728	337 out of 5,728 applicants to receive 50 H Shares	0.20%
2,000	5,249	338 out of 5,249 applicants to receive 50 H Shares	0.16%
2,500	3,749	259 out of 3,749 applicants to receive 50 H Shares	0.14%
3,000	3,635	267 out of 3,635 applicants to receive 50 H Shares	0.12%
3,500	2,555	197 out of 2,555 applicants to receive 50 H Shares	0.11%
4,000	2,555	205 out of 2,555 applicants to receive 50 H Shares	0.10%
4,500	2,094	175 out of 2,094 applicants to receive 50 H Shares	0.09%
5,000	4,918	424 out of 4,918 applicants to receive 50 H Shares	0.09%
6,000	3,647	333 out of 3,647 applicants to receive 50 H Shares	0.08%
7,000	2,614	251 out of 2,614 applicants to receive 50 H Shares	0.07%
8,000	2,314	232 out of 2,314 applicants to receive 50 H Shares	0.06%
9,000	2,165	225 out of 2,165 applicants to receive 50 H Shares	0.06%
10,000	14,544	1,559 out of 14,544 applicants to receive 50 H Shares	0.05%
20,000	9,347	1,249 out of 9,347 applicants to receive 50 H Shares	0.03%
30,000	7,263	1,103 out of 7,263 applicants to receive 50 H Shares	0.03%
40,000	5,370	894 out of 5,370 applicants to receive 50 H Shares	0.02%
50,000	9,667	1,726 out of 9,667 applicants to receive 50 H Shares	0.02%
<b>Total</b>	<b>231,973</b>	<b>Total number of Pool A successful applicants: 14,194</b>	

## Pool B

Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of H Shares applied for
60,000	8,776	2,107 out of 8,776 applicants to receive 50 H Shares	0.02%
70,000	3,101	824 out of 3,101 applicants to receive 50 H Shares	0.02%
80,000	2,312	671 out of 2,312 applicants to receive 50 H Shares	0.02%
90,000	1,923	603 out of 1,923 applicants to receive 50 H Shares	0.02%
100,000	8,879	2,980 out of 8,879 applicants to receive 50 H Shares	0.02%
200,000	4,254	2,249 out of 4,254 applicants to receive 50 H Shares	0.01%
300,000	1,758	1,213 out of 1,758 applicants to receive 50 H Shares	0.01%
400,000	976	813 out of 976 applicants to receive 50 H Shares	0.01%
500,000	630	608 out of 630 applicants to receive 50 H Shares	0.01%
600,000	429	50 H Shares plus 38 out of 429 applicants to receive an additional 50 H Shares	0.01%
709,650	1,366	50 H Shares plus 292 out of 1,366 applicants to receive an additional 50 H Shares	0.01%
<b>Total</b>	<b><u>34,404</u></b>	<b>Total number of Pool B successful applicants: 13,863</b>	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

## COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

## OTHERS/ADDITIONAL INFORMATION

### Allocation of Offer Shares to Certain Existing Shareholders and/or Their Close Associates

#### *As Cornerstone Investors*

The Company has sought, and the Stock Exchange has given, a consent under paragraph 1C(2) of the Placing Guidelines to permit TruMed Master Fund and TruMed Innovation Fund (collectively, the “**TruMed Funds**”) to participate in the Global Offering as Cornerstone Investors on the following basis as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide, subject to the conditions as follows:

- (a) the Company will comply with the public float requirement under Rule 19A.13A and the free float requirement under Rule 19A.13C of the Listing Rules;
- (b) the Offer Shares to be subscribed by and allocated to TruMed Master Fund and TruMed Innovation Fund (each a close associate of an existing Shareholder) as cornerstone investors under the Global Offering will be at the Offer Price and on substantially the same terms as other cornerstone investors (including being subject to a six-month lock up arrangement following the Listing), and TruMed Funds will pay and settle in full for the Offer Shares before dealings commence on the Listing Date;
- (c) the Company, the Sole Sponsor and the Overall Coordinators confirm that no preferential treatment has been, nor will be, given to each of TruMed Funds as a cornerstone investor by virtue of its relationship with the Company in any allocation in the Global Offering, other than the preferential treatment of assured entitlement under the cornerstone investment with TruMed Funds which follows the principles set out in Chapters 2.3 and 4.15 of the Guide, and that the terms of the cornerstone investment agreement of TruMed Funds are substantially the same as the other cornerstone investment agreements;
- (d) each of the Company, the Sole Sponsor and the Overall Coordinators has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide; and
- (e) details of the allocation of the Offer Shares to each of TruMed Funds as a cornerstone investor in the Global Offering have been disclosed in the allotment results announcement of the Company.

Such allocations of Offer Shares to the close associates of an existing Shareholder are in compliance with all the conditions under the consent given by the Stock Exchange.

### ***As Placees***

The Company has applied, and the Stock Exchange has given, a consent under paragraph 1C(2) of the Placing Guidelines to permit certain close associates of existing Shareholders to participate in the Global Offering as placees on the following basis as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide, subject to the following conditions:

- (a) None of the Permitted Participants, together with the involved existing Shareholder, is, and will be, a core connected person of the Company, the allocation to the Permitted Participants will not affect the Company's ability to satisfy the public float requirement under Rule 19A.13A of the Listing Rules and the free float requirement under Rule 19A.13C of the Listing Rules;
- (b) each of the Sole Sponsor and the Overall Coordinators confirms that no preferential treatment in allocation has been, nor will be, given to each of OFC Tech, Changshu Kunsheng and Changshu Guofa by virtue of their respective relationship with the relevant existing Shareholders of the Company;
- (c) the Company confirms that no preferential treatment in allocation has been, nor will be, given to each of OFC Tech, Changshu Kunsheng and Changshu Guofa by virtue of their respective relationship with the relevant existing Shareholders of the Company;
- (d) each of the Company, the Sole Sponsor and the Overall Coordinators has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide; and
- (e) the relevant information in respect of the allocation to the Permitted Participants has been disclosed in the allotment results announcement.

For details of the allocations of Offer Shares to certain existing Shareholders and/or their close associates, please refer to the section headed "Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained" in this announcement.

## Allocation of Offer Shares to Connected Clients

### *As Cornerstone Investors*

The Company has sought, and the Stock Exchange has given, a consent under paragraph 1C(1) of the Placing Guidelines to allow each of VPHKL and VPL to subscribe for Offer Shares as a Cornerstone Investor on the following basis as set out in Chapter 4.15 of the Guide, subject to the conditions as follows:

- (a) each of VPHKL and VPL will hold H Shares allocated to it on a discretionary basis and on behalf of independent third parties;
- (b) the relevant cornerstone investment agreement of each of VPHKL and VPL does not contain any material terms which are more favorable to it than those in other cornerstone investment agreements;
- (c) no preferential treatment has been, nor will be, given to each of VPHKL and VPL by virtue of its relationship with GF Securities (Hong Kong) Brokerage Limited (“**GF Securities (Hong Kong) Brokerage**”) in any allocation of Offer Shares in the Global Offering (other than the assured entitlement under the relevant cornerstone investment agreement following the principles set out in Chapter 4.15 of the Guide);
- (d) GF Securities (Hong Kong) Brokerage has not participated, and will not participate, in the decision-making process or relevant discussions relating to allocation of Offer Shares to VPHKL and VPL as cornerstone investors;
- (e) each of VPHKL and VPL has confirmed that to the best of its knowledge and belief, it has not received and will not receive preferential treatment in the allocation of Offer Shares in the Global Offering as cornerstone investors by virtue of its relationship with GF Securities (Hong Kong) Brokerage (other than the assured entitlement under the relevant cornerstone investment agreement following the principles set out in Chapter 4.15 of the Guide);
- (f) each of the Company, the Overall Coordinators including GF Securities (Hong Kong) Brokerage as one of the Overall Coordinators, VPHKL, VPL and GF Securities (Hong Kong) Brokerage has provided the Stock Exchange with written confirmations in accordance with Chapter 4.15 of the Guide; and
- (g) details of the cornerstone investments and details of the allocations have been disclosed in the allotment results announcement of the Company.

Such allocations of Offer Shares to connected clients are in compliance with all the conditions under the consent given by the Stock Exchange.

## As Placees

Under the International Offering, certain Offer Shares were placed to connected clients of a connected distributor pursuant to the Placing Guidelines. Details of the placement to connected clients are set out below.

No.	Connected distributor	Connected Client	Relationship with the connected distributor	Basis of holding securities	Number of Offer Shares to be allocated	% of total Offer Shares in the Global Offering <sup>(1)</sup>	% of total issued shares capital immediately upon the completion of Global Offering <sup>(1)</sup>
1.	GF Securities (Hong Kong) Brokerage Limited (“ <b>GF Securities (Hong Kong) Brokerage</b> ”)	GF International Investment Management Limited (“ <b>GF International Investment</b> ”) <sup>(2)</sup>	GF International Investment is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	806,850	5.68%	1.09%
2.		E Fund Management Co., Ltd. (“ <b>E Fund</b> ”) <sup>(3)</sup>	E Fund is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	57,450	0.40%	0.08%
3.		E Fund Management (Hong Kong) Co., Ltd. (“ <b>E Fund HK</b> ”) <sup>(3)</sup>	E Fund HK is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	7,100	0.05%	0.01%
4.		GF Securities Asset Management (Guangdong) Co., Ltd. (“ <b>GF Securities AM</b> ”) <sup>(4)</sup>	GF Securities AM is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Non-discretionary	8,500	0.06%	0.01%
5.	Orient Securities (Hong Kong) Limited (“ <b>Orient Securities</b> ”)	Orient Asset Management (Hong Kong) Limited (“ <b>Orient AM</b> ”) <sup>(5)</sup>	Orient AM is a member of the same group of Orient Securities.	Discretionary	800	0.01%	0.001%

### Notes:

- (1) Assuming the Over-allotment Option is not exercised.
- (2) GF International Investment will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors (the “**GF International Investment Ultimate Clients**”). GF International Investment is an indirect non-wholly owned subsidiary of GF Securities Co., Ltd. (廣發証券股份有限公司) (“**GF Securities**”), a company listed on the Shenzhen Stock Exchange (stock code: 000776.SZ) and the Stock Exchange (stock code: 01776.HK). GF Securities (Hong Kong) Brokerage is an indirect wholly-owned subsidiary of GF Securities. Accordingly, GF International Investment is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.

GF International Investment is to invest on a discretionary basis on behalf of the GF International Investment Ultimate Clients which are independent third parties and no proprietary money is used for the subscribing. To the best knowledge of GF International Investment, each of GF International Investment Ultimate Clients is an independent third party of the Company, its subsidiaries, its substantial shareholders, GF International Investment, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage. No ultimate beneficial owner holds 30% or more interest in the funds.

GF International Investment is investing on behalf of certain collective investment schemes which are not authorized by the SFC, details of which are as follow:

<b>Fund Name</b>	<b>Fund Manager</b>	<b>Identity of ultimate beneficial owner (“UBO”) holding 30% or more interest</b>
Frontline Investment Master SPC – GF Luminous Fund SP	GF International Investment	Not applicable as there is no UBO holding 30% or more interest
Frontline Investment Master SPC – GF Vision Fund SP	GF International Investment	Not applicable as there is no UBO holding 30% or more interest
Frontline Investment Master SPC – GF Bonanza Fund SP	GF International Investment	Not applicable as there is no UBO holding 30% or more interest
Frontline Investment Master SPC – GF Curation Equity Fund SP	GF International Investment	Not applicable as there is no UBO holding 30% or more interest
Frontline Investment Master SPC – Golden Stone Fund SP	GF International Investment	Not applicable as there is no UBO holding 30% or more interest
Frontline Investment Master SPC – GF Navigation Fund SP	GF International Investment	Not applicable as there is no UBO holding 30% or more interest

In addition to the funds disclosed above, GF International Investment is also expected to hold the Offer Shares on behalf of one SFC authorized fund, namely GFI Global Select Equity Fund.

- (3) Each of E Fund and E Fund HK will hold the Offer Shares in its capacity as the discretionary fund manager managing the sub funds on behalf of the underlying clients (the “**E Fund Ultimate Clients**”). GF Securities (Hong Kong) Brokerage is an indirect wholly-owned subsidiary of GF Securities, which in turn holds 22.65% of the issued share capital of E Fund. E Fund HK is a wholly-owned subsidiary of E Fund. Therefore, each of E Fund and E Fund HK constitutes a member of the same group with GF Securities (Hong Kong) Brokerage.

E Fund and E Fund HK are to invest on discretionary basis on behalf of the E Fund Ultimate Clients which are independent third parties and no proprietary money is used for the subscribing. To the best knowledge of E Fund and E Fund HK, (i) each of the E Fund Ultimate Clients is an independent third party of the Company, its subsidiaries, its substantial shareholders, E Fund, E Fund HK, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage; and (ii) neither E Fund or E Fund HK is a collective investment scheme which is not authorised by the SFC.

Details of the E Fund Ultimate Clients are set out below:

<b>Fund Name</b>	<b>Fund manager</b>	<b>Identity of ultimate beneficial owner (“UBO”) holding 30% or more interest</b>
E Fund Global Asset Allocation Hybrid Fund	E Fund	Not applicable as there is no UBO holding 30% or more interest.
E Fund Global Healthcare Sector Sponsored Hybrid Fund	E Fund	Not applicable as there is no UBO holding 30% or more interest.
E Fund S&P Global Luxury Enhanced Index Fund	E Fund	Not applicable as there is no UBO holding 30% or more interest.
E Fund (HK) Global Allocation Fund SP I	E Fund HK	Cinda Sino-Rock Investment Limited, whose UBO holding 30% or more interest is China Cinda Asset Management Co., Ltd. (stock code: 1359.HK).
E FUND (HK) NEO OPPORTUNITY SP I	E Fund HK	Not applicable as there is no UBO holding 30% or more interest.
E Fund (HK) China Equity Dividend Fund	E Fund HK	Not applicable as there is no UBO holding 30% or more interest.

- (4) GF Securities AM is a direct wholly-owned subsidiary of GF Securities. GF Securities (Hong Kong) Brokerage is an indirect wholly-owned subsidiary of GF Securities. Accordingly, GF Securities AM is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.

Each of the ultimate clients of GF Securities AM (the “**GF Securities AM Ultimate Clients**”) has engaged GF Securities AM, an asset manager that is qualified domestic institutional investor as approved by the relevant PRC authority, in the name of the asset management plans as disclosed below, to subscribe for and hold the Offer Shares as a placee under the International Offering on behalf of the relevant GF Securities AM Ultimate Client on a non-discretionary basis. GF Securities AM, in the name of the asset management plans as disclosed below, will hold the legal title of the Offer Shares, and the economic risks and return of the Offer Shares will pass through to the GF Securities AM Ultimate Clients.

Details of the GF Securities AM Ultimate Clients are set out as below:

Name of the GF Securities AM Ultimate Clients	Name of the asset management plan
Shenwan Hongyuan Group Co., Ltd. (申萬宏源集團股份有限公司, a company listed on the Stock Exchange (stock code: 6806) and the Shenzhen Stock Exchange (stock code: 000166))	GF Asset Management Wanxiang No. 1 Single Asset Management Plan (廣發資管萬享1號單一資產管理計劃)
He Wei (賀偉)	GF Asset Management Excellence Diversified Allocation No. 37 Single Asset Management Plan (廣發資管卓越多元配置37號單一資產管理計劃)
Zhonghe Capital Cultivation 920 Private Securities Investment Fund (中和資本耕耘920號私募證券投資基金), whose ultimate beneficial owner is Zhang Jingting (張敬庭)	GF Asset Management Hong Kong Equity Diversified Strategy No. 7 Single Asset Management Plan

To the best knowledge of GF Securities AM, (i) each of the GF Securities AM Ultimate Clients is an independent third party of the Company, its subsidiaries, its substantial shareholders, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage; and (ii) GF Securities AM is not a collective investment scheme which is not authorized by the SFC nor is expected to hold the Offer Shares on behalf of such scheme.

- (5) Orient AM will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of its underlying clients. Both Orient AM and Orient Securities is a wholly-owned subsidiary of Orient Securities International Financial Group Limited. Therefore, Orient AM is a member of the same group of Orient Securities. To the best knowledge of Orient AM, (i) each of the underlying clients of Orient AM is an independent third party of the Company, its subsidiaries, its substantial shareholders, Orient AM, Orient Securities and the companies which are members of the same group of companies as Orient Securities; and (ii) no ultimate beneficial owner holds 30% or more interest in each of the underlying clients of Orient AM, except that one discretionary account managed by Orient AM, namely Orient Asset Mgt (HK) Ltd-OSR Selective No.4, is wholly owned by an individual investor who is an independent third party.

Orient AM is investing on behalf of certain collective investment schemes which are not authorized by the SFC, details of which are as follow:

Fund Name	Types and values of assets under management	Whether the scheme is publicly marketed	Scheme establishment date	Identities of the general partners and the 20 largest limited partners of the scheme where applicable	Identity of the scheme administrator	Relationships among the scheme, the ultimate beneficial owner(s), Orient Securities and the Company
Orient Asset Mgt (HK) Ltd-OSR Selective No.4	Private Fund, US\$20 million	No	August 22, 2024	Not applicable as it is not in partnership structure and does not have any general partner or limited partner	Agricultural Bank of China Limited, Hong Kong Branch	The scheme and ultimate beneficial owners are independent third parties of Orient Securities, the Company and the Controlling Shareholders of the Company.
ORIENT SUN RISE FUND SERIES SPC – ORIENT SUN RISE OVERSEAS STABLE FUND SEGREGATED PORTFOLIO	Private Fund, US\$5 million	No	November 18, 2025	Not applicable as it is not in partnership structure and does not have any general partner or limited partner	Agricultural Bank of China Limited, Hong Kong Branch	The scheme and ultimate beneficial owners are independent third parties of Orient Securities, the Company and the Controlling Shareholders of the Company.

The Company has applied to the Stock Exchange for, and the Stock Exchange has given, a consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the connected clients listed above. The allocations of Offer Shares to such connected clients are in compliance with all the conditions under the consent given by the Stock Exchange.

## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus dated May 28, 2026 issued by LongBio Pharma (Suzhou) Co., Ltd. (天辰生物醫藥(蘇州)股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

\* *Potential investors of the Offer Shares should note that the Sole Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Friday, June 5, 2026).*

## PUBLIC FLOAT AND FREE FLOAT

Immediately upon completion of the Global Offering (before any exercise of the Over-allotment Option) and the conversion of Unlisted Shares into H Shares, an aggregate of 33,698,881 H Shares, representing approximately 45.42% of the total issued share capital of the Company will be counted towards the public float. Pursuant to Rule 19A.13A(1) of the Listing Rules, where the expected market value at the time of Listing exceeds HK\$6 billion but not exceeding HK\$30 billion, the minimum number of H shares held by the public at the time of Listing as a percentage of the total number of shares in the class to which H shares belong shall be the higher of: (i) the percentage that would result in the expected market value of H shares held by the public to be HK\$1,500,000,000 at the time of Listing; and (ii) 15%. Based on the Offer Price of HK\$96.06 per Offer Share, the expected market capitalization of the Company’s H Shares would exceed HK\$6 billion and the percentage that would result in the expected market value of H shares held by the public to be HK\$1,500,000,000 at the time of Listing would be 21.05%. Therefore, the Company will be able to meet the minimum public float requirement under Rule 19A.13A(1) of the Listing Rules.

Under the applicable PRC laws, all existing Shareholders are subject to a lock-up period of twelve months following the Listing Date. Each of the Cornerstone Investors has agreed to a lock-up period of six months following the Listing Date. As such, H Shares held by all existing Shareholders and the Cornerstone Investors are not counted towards the free float of the H Shares at the time of Listing. Based on the Offer Price of HK\$96.06 per Offer Share, the expected market value of the H Shares held by the public and not subject to disposal restrictions exceeds HK\$600,000,000. As such, the Company satisfies the free float requirement under Rule 19A.13C(1)(b) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering and the conversion of Unlisted Shares into H Shares, (i) the three largest public Shareholders do not hold more than 50% of the H Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; (ii) there will not be any new substantial Shareholder (as defined in the Listing Rules) immediately after the Global Offering; (iii) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; and (iv) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Friday, June 5, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Friday, June 5, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, June 5, 2026 (Hong Kong time). The H Shares will be traded in board lots of 50 H Shares each, and the stock code of the H Shares will be 01779.

By order of the Board  
**LongBio Pharma (Suzhou) Co., Ltd.**  
**Liu Heng**  
*Chairman of the Board and executive Director*

Hong Kong, June 4, 2026

*As of the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Dr. CHEN Kan as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.*